Triplet Not Always Better Than Doublet in mCSPC : vimarsana.

First-line systemic therapy in patients with metastatic castration-sensitive prostate cancer should be based on individual disease and patient characteristics, results of a meta-analysis suggest.

Related Keywords

New York , United States , Boston , Massachusetts , Memorial Sloan Kettering Cancer Center , Dana Farber Cancer Institute , Howardi Scher , Deaglanj Mchugh , , Irbaz Bin Riaz , Prostate Carcinoma , Alignant Prostate Neoplasm , Prostate Cancer , Ancer Prostate , Cancer , Alignant Neoplasia , Arcinoma , Metastasis , Meta Analysis , Prostatic , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Chemotherapy , Clinical Research , Clinical Trials , Linical Studies ,